Added to YB: 2026-10-14
Pitch date: 2026-10-12
NVO [bullish]
Novo Nordisk A/S
+1.24%
current return
Author Info
Kontra Invest is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 38.74
Price Target
N/A
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
turnaround
Novo ($NVO) is turning but there is still a long road ahead.
NVO (update): Novo’s turn looks real: Wegovy pill prescriptions are plateauing near 180,000 after reaching 184,000, combined oral GLP-1 prescriptions have risen 107% since Foundayo’s launch, and Novo retains 76% share while oral diabetes and Wegovy HD are growing. At about DKK 254, the shares trade at ~11x consensus 2026 EPS with a 4.6% trailing yield. The threat is oral starter-dose share sliding to ~60%; adjusted sales and operating-profit guidance remains flat to down 6% at CER.
Read full article (4 min)